Technical Analysis for XTLB - XTL Biopharmaceuticals Ltd.

Grade Last Price % Change Price Change
B 1.16 31.69% 0.28
XTLB closed up 31.69 percent on Monday, March 18, 2024, on 6.74 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
New Uptrend Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%

   Recent Intraday Alerts

Alert Time
Possible Pocket Pivot about 13 hours ago
60 Minute Opening Range Breakout about 14 hours ago
2x Volume Pace about 15 hours ago
1.5x Volume Pace about 15 hours ago
3x Volume Pace about 15 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

XTL Biopharmaceuticals Ltd. Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. It is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C. The company's lead drug candidate is recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma blood cancer, as well as for the treatment of severe anemia. The rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma blood cancer. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases, with focus on schizophrenia. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Herzliya, Israel.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Natural Sciences Pharmacy Clinical Development Medication Pharmaceutical Products FDA Schizophrenia Multiple Myeloma Orphan Drug Anemia Hepatitis C Drug Design Antipsychotic Erythropoietin

Is XTLB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.54
52 Week Low 0.75
Average Volume 3,828
200-Day Moving Average 0.97
50-Day Moving Average 0.90
20-Day Moving Average 0.90
10-Day Moving Average 0.94
Average True Range 0.07
RSI (14) 69.97
ADX 33.02
+DI 40.01
-DI 28.02
Chandelier Exit (Long, 3 ATRs) 0.96
Chandelier Exit (Short, 3 ATRs) 0.99
Upper Bollinger Bands 1.05
Lower Bollinger Band 0.75
Percent B (%b) 1.38
BandWidth 33.43
MACD Line 0.03
MACD Signal Line 0.01
MACD Histogram 0.0189
Fundamentals Value
Market Cap 6.31 Million
Num Shares 5.45 Million
EPS -0.40
Price-to-Earnings (P/E) Ratio -2.90
Price-to-Sales 0.00
Price-to-Book 1.90
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.45
Resistance 3 (R3) 1.42 1.30 1.40
Resistance 2 (R2) 1.30 1.23 1.31 1.38
Resistance 1 (R1) 1.23 1.18 1.27 1.25 1.37
Pivot Point 1.11 1.11 1.13 1.12 1.11
Support 1 (S1) 1.04 1.04 1.07 1.06 0.95
Support 2 (S2) 0.92 0.99 0.93 0.94
Support 3 (S3) 0.85 0.92 0.92
Support 4 (S4) 0.87